SOX7与SOX9在鉴别前列腺癌与前列腺增生中的作用

目的 探讨SOX7和SOX9在鉴别前列腺癌与前列腺增生中的临床意义。方法 收集147例前列腺癌与28例前列腺增生患者病理组织及临床资料,运用免疫组化实验分析SOX7与SOX9的表达及其作用。结果 SOX7在前列腺癌组织中表现为低表达（P=0.025）,而SOX9为高表达（P=0.043）,SOX7与SOX9呈负相关（r=-0.263,P=0.001）。将SOX7与SOX9免疫组化评分与前列腺癌病理参数相结合进行分析,发现SOX7在血清PSA水平〈10ng/ml（P=0.048）、Gleason评分〈7（P=0.018）、肿瘤TNM分期〈T2a（P〈0.001）和病理分期T2a~T2c（P=0.002）前列腺癌患者中有较高的表达,而SOX9在Gleason评分≥7（P=0.001）和肿瘤TNM分期≥T2a（P=0.005）的前列腺癌患者中有较高的表达,差异有统计学意义。结论 通过检测SOX7和SOX9的水平可鉴别前列腺癌与前列腺增生,并可以初步判断前列腺癌的恶性程度。 更多还原

The role of SOX7 and SOX9 in differentiating prostate cancer from benign prostatic hyperplasia

Objective To explore the clinical significance of SOX7 and SOX9 in differentiating prostate cancer （PCa） from benign prostatic hyperplasia （BPH）. Methods 147 cases of PCa and 28 cases of BPH were retrospectively analyzed. The histopathological and clinical data were collected, and immunohistochemistry （IHC） were used to analysis SOX7 and SOX9 expression in PCa and BPH. Results In PCa tissues SOX7 is lowly expressed （P：0. 025） while SOX9 is highly expressed （P：0. 043）. SOX7 negatively correlated with SOX9 （r= -0. 263, P=0. 001）. Combined expression score of SOX7 and SOX9 with the clinicopathological parameters of corresponding PCa patients, we found that SOX7 has a higher expression in patients with serum PSA level of less than 10 ng/ml （P：0. 048）, Gleason score less than 7 （P=0. 018）, TNM stage less than T2a （P〈0. 001） and pathological stage T2a-T2c （P=0. 002）, while SOX9 has a higher expression in patients with Gleason score greater than or equal to 7 （P=0. 001） and TNM stage graeter than or equal to T2a （P= 0. 005）, and there was a significantly statistical significance. Conclusions By detecting the level of SOX7 and SOX9 we can identify PCa and BPH, and can determine the degree of malignancy of PCa.